-
Henlius Biotech Partners with Shantou Central Hospital for Clinical Study Collaboration
•
China-based Shanghai Henlius Biotech (HKG: 2696) has announced a strategic clinical study cooperation agreement with Shantou Central Hospital. The partnership aims to leverage Henlius’s clinical development and operational expertise with Shantou Central Hospital’s leading disciplinary advantages and comprehensive medical service capabilities. The collaboration will focus on scientific research exchange, personnel…
-
AnchorDx Initiates US Registrational Study for UriFind Urothelial Carcinoma Diagnostic
•
China-based AnchorDx Medical Co., Ltd, a specialist in methylation high-throughput sequencing, has announced the initiation of a registrational clinical study for its urothelial carcinoma (UC) early diagnostic product UriFind in the United States, alongside the enrollment of the first patient. The study aims to verify UriFind’s performance and support the…
-
Biocytogen Announces Successful Development of Fully-Human Nano Antibody RenNano
•
Biocytogen (Beijing) Co., Ltd has announced the successful research and development of a fully-human nano antibody RenNano, following its previous achievements with RenMab and RenLite. The China-based Contract Research Organization (CRO) is now capable of developing fully-human monoclonal antibodies (mAbs), fully-human bispecific antibodies (BsAbs), and fully-human nano antibodies. RenNano ProfileThe…
-
Kanghong Pharma Receives FDA Approval for KH631 Gene Therapy Trial
•
China-based Chengdu Kanghong Pharmaceutical Group Co., Ltd (SHE: 002773) has announced receiving clinical trial approval from the US FDA for its Category 1 innovative gene therapy eye injection KH631. The targeted indication is neovascular (wet) age-related macular degeneration (nAMD), a leading cause of vision loss in older adults. KH631 ProfileKH631…
-
Saint Medical Raises Pre-Series B Funding for Structural Heart Disease Solutions
•
Saint Medical Technology, a Nanjing-based medical device maker specializing in valvular disease solutions, has reportedly raised “tens of millions” of renminbi in a Pre-Series B financing round. The round was led by Jinpu Intelligent Manufacturing Fund, with participation from Wuxi Capital and Hexingcheng Fund. The proceeds will be used to…
-
Frontier Biotechnologies Gains CDE Approval for FB2001 COVID-19 Inhalant Study
•
China-based Frontier Biotechnologies Inc. (SHA: 688221) has announced receiving approval from the Center for Drug Evaluation (CDE) to conduct a Phase II/III clinical study assessing its FB2001 atomized inhalant bofutrelvir in mild and common COVID-19 patients. This marks a significant step forward in the development of innovative treatments for COVID-19.…
-
Alphamab Oncology and CSPC Announce Positive Phase II Data for KN026 in HER2-Positive Gastric Cancer
•
China-based Alphamab Oncology (HKG: 9966) and CSPC Pharmaceutical Group Ltd (HKG: 1093) have announced the publication of Phase II clinical study data for KN026 as a second-line treatment for HER2-positive locally advanced unresectable or metastatic gastric cancer or gastroesophageal junction cancer (GC/GEJ) in the European Journal of Cancer (IF=10.002). The…
-
Kexing Pharma Receives Ethical Approval for Phase II Study of SHEN26 COVID-19 Drug
•
China-based Kexing Pharmaceutical (SHA: 688136) has announced receiving ethical approval to conduct a Phase II clinical study for its SHEN26, an oral small-molecule COVID-19 drug co-developed with Shenzhen Antaiwei Biopharmaceutical Co., Ltd. The study aims to assess the efficacy and safety of SHEN26 in mild and common COVID-19 cases. Study…
